Today we continue our weekly installment highlighting the best of the patent blogosphere from the past week. If there are any patent blogs you think should be highlighted by our Top 5, please comment on this post and we’ll check them out.
1) Patently-O: Deference to BPAI: Federal Circuit Affirms Ruling that Monsanto’s Late-Filed Claims Win Priority over Pioneer’s Issued Patent – This post discusses the background and interference claim in Pioneer Hi-Bred International, Inc. (“Pioneer”) v. Monsanto Technology LLC, and how appellate panel gave clear deference to the USPTO Board of Patent Appeals and Interferences – repeatedly focusing on whether the board committed reversible error rather than jumping to the underlying question of whether the Board made the correct decision.
2) IP Kat: Patent Translate – EPO and Google launch new service – This post reports how the European Patent Office launched Patent Translate, a new machine translation service which utilizes Google’s Translate technology and enables translation from and to English for French, German, Spanish, Italian, Portuguese and Swedish, covering approximately 90% of all patents issued in Europe.
3) Patents Post-Grant: USPTO Deadlines Fast Approaching for Comments on AIA Rule Making – This post provides the relevant deadlines for submitting comments regarding the new rules to implement the various provisions of the AIA, and exlpains how the USPTO has grouped the various rule packages.
4) IP Watchdog: Follow the Money – Will the ITC Lose its Patent Jurisdiction? – This post, written by guest author Bernard J. “Barney” Cassidy, details the impact of lobbying groups like the ITC Working Group in Washington on non-practicing entities and the future of legislation revolving around the ITC.
5) Delaware IP Law Blog: Chief Judge Sleet Construes Claims of Pfizer Patents Covering Cancer Treatment Drug – This post discusses Pfizer Inc. v. Mylan Pharm., Inc., C.A. No. 10-528-GMS (D. Del. Feb. 21, 2012), and how Judge Sleet rejected the defendant’s attempts to add a limitation that the method or effect must be in vitro. It explains how the judge defined key terms in the claim.
Tags: AIA Rule Making, Board of Patent Appeals & Interferences, European Patent Office, ITC, patent lobbying, Patent Translate, USPTO
You share in the PLI Practice Center community, so we just ask that you keep things civil. Leave out the personal attacks. Do not use profanity, ethnic or racial slurs, or take shots at anyone's sexual orientation or religion. If you can't be nice, we reserve the right to remove your material and ban users who violate our Terms of Service.